Climate change is an environmental problem that has a significant effect on the continued existence of life, including human beings, and efforts to prevent it are now a major challenge for the global community. Mitsubishi Tanabe Pharma Group has positioned climate change initiatives as an important management theme and is promoting the reduction of greenhouse gas (below, "GHG") emissions resulting from its business activities.

Scope 3 GHG emissions in the supply chain emitted after sales and procurement of raw materials were largest in category 1, accounting for 95.6% of Scope 3. The Group has been working with other pharmaceutical companies to promote joint distribution of ethical drugs in Japan since fiscal 2022, which reduces the number of vehicles used for operations and thus lowers GHG emissions.

In our carbon neutrality action formulated in fiscal 2023, we created a roadmap for the introduction of renewable energy, the switch to the use of next-generation vehicles as company-owned vehicles, and the conversion of fuels used in boilers and other large-scale equipment.
With regard to the introduction of renewable energy, we will promote the switch to renewable energy by moving to electric power from renewable energy sources at factories in Japan by 2025, and by all other offices in Japan by 2030.

The Group is actively promoting energy conservation activities.
At our domestic and overseas bases, we are continuously replacing lights with LED lighting, controlling the blinking of lights with sensors, as well as promoting the update of energy saving equipment, and the shutdown of operations in manufacturing areas during long vacation periods. We are also engaged in daily energy-conserving activities such as energy-saving campaigns at all bases to educate employees and recommend turning off lights and equipment power when not in use.

The Group is shifting steadily from gasoline-powered vehicles to hybrid vehicles and promoting eco-driving to reduce GHG emissions from company-owned vehicles (switch to hybrid vehicles planned for completion by fiscal 2027).

Use of renewable energy that does not emit GHG is an effective measure to contribute to climate change mitigation.

The Group has installed solar power generating equipment at Mitsubishi Tanabe Pharma Korea (Hyangnam Plant), and carbon-free power has been installed at the Shonan Office and at some Group offices in Europe. Going forward, we will consider switching to electricity from renewable sources for procurement of power at other major Group bases, based on our carbon neutrality action plan.

The Group is working to prevent leaks of fluorocarbons, which add to the effects of ozone layer depletion and greenhouse gases. Equipment containing fluorocarbons installed in domestic bases is properly managed with a ledger in accordance with the revised Law Concerning the Discharge and Control of Fluorocarbons which came into effect in 2020. In addition, we comply with installation standards and conduct regular equipment inspections and when disposing of the equipment, we recover and destroy the fluorocarbons and maintain a record of this for three years.
Furthermore, when installing equipment containing fluorocarbons, we select a model that takes into account global warming potential and energy-saving performance.

In fiscal 2023, at domestic production and research bases, the leakage volume of fluorocarbons was 43kg (74 t-CO₂ equivalent.) The CO₂-equivalent leakage volumes for domestic Group companies were below the threshold for reporting to the national government for all years since 2015 when the leakage reporting system was established.